Skip to main
ATAI

ATAI Stock Forecast & Price Target

ATAI Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtaiBeckley is a clinical-stage biopharmaceutical company with a strong pipeline of novel therapies for treatment-resistant depression (TRD) and social anxiety disorder. The company's Phase 2 trials have shown positive results, with a significant reduction in symptoms and a high percentage of responders and remission. With a fully funded research and development program and a leadership position in the short-acting psychedelics market, AtaiBeckley is well positioned to capture a significant share of the multi-billion dollar TRD market. Upcoming catalysts, including Phase 3 trial initiation and topline Phase 2 data, make AtaiBeckley a compelling investment opportunity.

Bears say

AtaiBeckley is facing challenges with their Phase 3 PARADIGM trial not meeting its primary endpoint of MADRS, but showed some improvement in those with EDS. Despite positive Phase 2b results for their BPL-003 drug, it is uncertain if the 25mg dose will continue to show improvements in the MADRS endpoint. With a completed enrollment of 585 participants for their upcoming Phase 3 CLARITY trial, the company is facing increased pressure to deliver positive results to justify the time and resources spent on their developing therapies.

ATAI has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atai Life Sciences BV (ATAI) Forecast

Analysts have given ATAI a Strong Buy based on their latest research and market trends.

According to 7 analysts, ATAI has a Strong Buy consensus rating as of Jun 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atai Life Sciences BV (ATAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.